{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:38:14Z","timestamp":1791074294876,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004434.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T00:00:00Z","timestamp":1362009600000}}],"reference-count":123,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004434.pub5","type":"journal-article","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T06:56:06Z","timestamp":1361602566000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Endothelin receptor antagonists for pulmonary arterial hypertension"],"prefix":"10.1002","author":[{"given":"Chao","family":"Liu","sequence":"first","affiliation":[{"name":"The First Hospital of Hebei Medical University; Donggang Road Shijiazhuang Hebei Province China 050031"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Fujian Medical University; Department of Hematology and Rheumatology; #20 Chazhong Road Fuzhou Fujian Province China 350005"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Gao","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University; Donggang Road Shijiazhuang Hebei Province China 050031"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Deng","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University; Donggang Road Shijiazhuang Hebei Province China 050031"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunshen","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University; Donggang Road Shijiazhuang Hebei Province China 050031"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"key":"10.1002\/14651858.CD004434.pub5-BIB0002|cit1","unstructured":"US Food and Drug Administration. Center for drug evaluation and research. Letairis (Ambrisentan) Tablets: Medical Review(s) http:\/\/www.fda.gov\/cder\/foi\/nda\/2007\/022081s000TOC.htm (Accessed March 20, 2008)"},{"issue":"23","key":"10.1002\/14651858.CD004434.pub5-BIB0001|cit2","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0004|cit3","unstructured":"US Food and Drug Administration. Center for drug evaluation and research. Letairis (Ambrisentan) Tablets: Medical Review(s) http:\/\/www.fda.gov\/cder\/foi\/nda\/2007\/022081s000TOC.htm (Accessed March 20, 2008)"},{"issue":"23","key":"10.1002\/14651858.CD004434.pub5-BIB0003|cit4","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","article-title":"Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies","volume":"149","author":"Barst","year":"2010","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0007|cit6","unstructured":"US Food and Drug Administration. Center for drug evaluation and research.Tracleer (Bosentan) Tablets: Medical Review(s) http:\/\/www.fda.gov\/cder\/foi\/nda\/2001\/21-290_Tracleer.htm"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub5-BIB0006|cit7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0009|cit8","unstructured":"US Food and Drug Administration. Center for drug evaluation and research.Tracleer (Bosentan) Tablets: Medical Review(s) http:\/\/www.fda.gov\/cder\/foi\/nda\/2001\/21-290_Tracleer.htm (Accessed March 20, 2008)"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub5-BIB0008|cit9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"The European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0011-393X(02)80029-7","article-title":"complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension","volume":"63","author":"Badesch","year":"2002","journal-title":"Current Therapeutic Research, Clinical & Experimental"},{"issue":"9288","key":"10.1002\/14651858.CD004434.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"issue":"9630","key":"10.1002\/14651858.CD004434.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD004434.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0735-1097(03)00121-9","article-title":"Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension","volume":"41","author":"Gali\u00e8","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD004434.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0017|cit16","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H-679-en6.pdf (Accessed March 22, 2008)"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0018|cit17","unstructured":"Therapeutic Goods Administration (TGA), Australia. Public Summary Documents by Product: Thelin http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/pbac-psd-sitaxentan-sodium-july07 (Accessed April 25, 2008)"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0016|cit18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Amercian Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0020|cit19","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H-679-en6.pdf Accessed March 22, 2008"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0019|cit20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Amercian Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0022|cit21","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H-679-en6.pdf (Accessed March 22, 2008)"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0021|cit22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Amercian Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0024|cit23","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H-679-en6.pdf (Accessed March 22, 2008)"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0025|cit24","unstructured":"Therapeutic Goods Administration (TGA), Australia. Public Summary Documents by Product: Thelin http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/pbac-psd-sitaxentan-sodium-july07 (Accessed April 25, 2008)"},{"issue":"10","key":"10.1002\/14651858.CD004434.pub5-BIB0023|cit25","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0027|cit26","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H-679-en6.pdf (Accessed March 22, 2008)"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0028|cit27","unstructured":"Therapeutic Goods Administration (TGA), Australia. Public Summary Documents by Product: Thelin http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/pbac-psd-sitaxentan-sodium-july07 (Accessed April 25, 2008)"},{"issue":"10","key":"10.1002\/14651858.CD004434.pub5-BIB0026|cit28","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0030|cit29","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H-679-en6.pdf (Accessed March 22, 2008)"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0031|cit30","unstructured":"Therapeutic Goods Administration (TGA), Australia. Public Summary Documents by Product: Thelin http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/pbac-psd-sitaxentan-sodium-july07 (Accessed April 25, 2008)"},{"issue":"10","key":"10.1002\/14651858.CD004434.pub5-BIB0029|cit31","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0032|cit32","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H-679-en6.pdf (Accessed March 22, 2008)"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0033|cit33","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H-679-en6.pdf (Accessed March 22, 2008)"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0034|cit34","unstructured":"European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/thelin\/H-679-en6.pdf (Accessed March 22, 2008)"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","article-title":"Exercise capacity and haemodynamics inpatients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies","volume":"149","author":"Barst","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension","volume":"30","author":"Barst","year":"2011","journal-title":"Journal of Heart & Lung Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.healun.2006.10.019","article-title":"Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan","volume":"26","author":"Benza","year":"2007","journal-title":"The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD004434.pub5-BIB0038|cit38","first-page":"574","article-title":"Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging","volume":"62","author":"Bose","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0039|cit39","unstructured":"Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00070590"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-007-0408-z","article-title":"Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil","volume":"64","author":"Burgess","year":"2008","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0041|cit41","unstructured":"Coyne TC Garces PC Kramer W No clinical interaction between sitaxsentan and sildenafil [Abstract] American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005 [A57] [Poster: K70]"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD004434.pub5-BIB0042|cit42","first-page":"S227","article-title":"Multicentered trial of tezosentan in cardiac surgery","volume":"57","author":"Denault","year":"2010","journal-title":"Canadian Journal of Anesthesia"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1161\/HYPERTENSIONAHA.111.175646","article-title":"Chronic selective endothelin a receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease","volume":"58","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1378\/chest.08-2222","article-title":"Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia","volume":"135","author":"Faoro","year":"2009","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0045|cit45","first-page":"112","article-title":"Bosentan improves exercise capacity in acute hypoxic subjects","volume":"64","author":"Faoro","year":"2009","journal-title":"Acta Cardiologica"},{"issue":"8","key":"10.1002\/14651858.CD004434.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0091270008319793","article-title":"Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: An ascending-dose study in healthy male volunteers","volume":"48","author":"Frey","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e8","year":"2005","journal-title":"Journal of the American College of Cardiology."},{"issue":"22","key":"10.1002\/14651858.CD004434.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0049|cit49","first-page":"262","article-title":"3-year survival of patients treated with sitaxentan sodium (Thelin) for pulmonary arterial hypertension","volume":"Abstract Supple","author":"Gali\u00e8","year":"2009","journal-title":"European Heart Journal"},{"issue":"Abstract Supple","key":"10.1002\/14651858.CD004434.pub5-BIB0050|cit50","first-page":"22","article-title":"Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH): Results from a phase II study","volume":"Conference Publ","author":"Gali\u00e8","year":"2010","journal-title":"European Heart Journal"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD004434.pub5-BIB0051|cit51","first-page":"A2513","article-title":"Long term use of imatinib In patients with severe pulmonary arterial hypertension [Abstract]","volume":"181","author":"Ghofrani","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Gillies HC Wang X Staehr P Zack J PAH therapy In HIV: Lack of drug-drug interaction between ambrisentan and ritonavir American Journal of Respiratory and Critical Care Medicine 2011 A5913","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A5913"},{"issue":"25","key":"10.1002\/14651858.CD004434.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1161\/01.CIR.101.25.2922","article-title":"Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure","volume":"101","author":"Givertz","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0054|cit54","unstructured":"Gomberg-Maitland M McLaughlin V Gulati M Rich S Arbor A Efficacy and safety of sildenafil and atorvastatin added to bosentan as therapy for pulmonary arterial hypertension [Abstract] American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005 [A57] [Poster: K18]"},{"issue":"7","key":"10.1002\/14651858.CD004434.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/0091270009351173","article-title":"Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers","volume":"50","author":"Gotzkowsky","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"The European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub5-BIB0057|cit57","first-page":"114","article-title":"Role of pulmonary hypertension and right ventricular dysfunction in aerobic exercise capacity limitation in normal volunteers at high altitude","volume":"64","author":"Huez","year":"2009","journal-title":"Acta Cardiologica"},{"issue":"9","key":"10.1002\/14651858.CD004434.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo-controlled, double-blinded trial","volume":"31","author":"Iversen","year":"2010","journal-title":"European Heart Journal"},{"issue":"25","key":"10.1002\/14651858.CD004434.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial","volume":"52","author":"Jais","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"2-3","key":"10.1002\/14651858.CD004434.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0167-5273(02)00182-1","article-title":"Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?","volume":"85","author":"Kalra","year":"2002","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000107791","article-title":"Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study","volume":"109","author":"Kaluski","year":"2008","journal-title":"Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000107791","article-title":"Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study","volume":"109","author":"Kaluski","year":"2008","journal-title":"Cardiology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-9-69","article-title":"A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy","volume":"9","author":"Kefford","year":"2010","journal-title":"Molecular Cancer"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","article-title":"BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"177","author":"King","year":"2008","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"8977","key":"10.1002\/14651858.CD004434.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","article-title":"Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure","volume":"346","author":"Kiowski","year":"1995","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1042\/CS20080241","article-title":"Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension","volume":"116","author":"Lee","year":"2009","journal-title":"Clinical science"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"McLaughlin VV Oudiz RJ Frost A Tapson VF Murali S Channick RN Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension American Journal of Respiratory & Critical Care Medicine 2006 1257 63","DOI":"10.1164\/rccm.200603-358OC"},{"issue":"18","key":"10.1002\/14651858.CD004434.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"14","key":"10.1002\/14651858.CD004434.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.106.618397","article-title":"Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension","volume":"114","author":"Mereles","year":"2006","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"Modesti PA Vanni S Morabito M Modesti A Marchetta M Gamberi T Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study Circulation 2006 1410 6","DOI":"10.1161\/CIRCULATIONAHA.105.605527"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1183\/09031936.00024410","article-title":"Pulmonary artery pressure limits exercise capacity at high altitude","volume":"36","author":"Naeije","year":"2010","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3999\/jscpt.41.301","article-title":"Pharmacokinetics of ambrisentan, a novel drug for treatment of Pulmonary Arterial Hypertension (PAH), in Japanese subjects","volume":"41","author":"Nakahara","year":"2010","journal-title":"Japanese Journal of Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0075|cit75","first-page":"474a","article-title":"Long-term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension","volume":"132","author":"Oudiz","year":"2007","journal-title":"Chest"},{"issue":"21","key":"10.1002\/14651858.CD004434.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0077|cit77","unstructured":"Efficacy and safety of tral bosentan on healing\/prevention of digital (finger) ulcers in scleroderma patients http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00077584"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jtcvs.2009.03.053","article-title":"Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension","volume":"139","author":"Reesink","year":"2010","journal-title":"Journal of Thoracic & Cardiovascular Surgery"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1183\/09031936.06.00095705","article-title":"A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension","volume":"27","author":"Robbins","year":"2006","journal-title":"European Respiratory Journal"},{"issue":"2-3","key":"10.1002\/14651858.CD004434.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.resp.2008.10.005","article-title":"Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude","volume":"165","author":"Seheult","year":"2009","journal-title":"Respiratory Physiology & Neurobiology"},{"issue":"7","key":"10.1002\/14651858.CD004434.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/art.27466","article-title":"Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis","volume":"62","author":"Seibold","year":"2010","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Shenoy PD Agarwal V Tadalafil: A new role in Raynaud's phenomenon? International Journal of Clinical Rheumatology 2011 115 7","DOI":"10.2217\/ijr.11.8"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD004434.pub5-BIB0083|cit83","first-page":"A2515","article-title":"Efficacy, safety and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a phase IIa study In pulmonary arterial hypertension (PAH)","volume":"181","author":"Simonneau","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1177\/0091270008324180","article-title":"Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers","volume":"48","author":"Spence","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1002\/jps.21789","article-title":"No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers","volume":"98","author":"Spence","year":"2009","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.2009.03541.x","article-title":"The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects","volume":"69","author":"Stavros","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.00011308","article-title":"A randomised, controlled trial of bosentan in severe COPD","volume":"32","author":"Stolz","year":"2008","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub5-BIB0088|cit88","first-page":"1","article-title":"Safety and feasibility of inhaled iloprost on exercise capacity in patients with pulmonary arterial hypertension","volume":"19","author":"Worthington","year":"2010","journal-title":"Heart Lung and Circulation"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","article-title":"Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects","volume":"48","author":"Wrishko","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0090|cit90","first-page":"629","article-title":"A randomized open label study comparing bosentan or sildenafil first-line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)","volume":"31 ( Abstract S","author":"Palazzini","year":"2010","journal-title":"European Heart Journal"},{"issue":"7382","key":"10.1002\/14651858.CD004434.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Statistics Notes: Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"issue":"18","key":"10.1002\/14651858.CD004434.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/CIRCULATIONAHA.108.847707","article-title":"Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies","volume":"121","author":"Archer","year":"2010","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1378\/chest.132.4_MeetingAbstracts.488b","article-title":"Ambrisentan therapy for pulmonary arterial hypertension: a comparison by pah etiology","volume":"132","author":"Badesch","year":"2007","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub5-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0096|cit96","unstructured":"Chen Y Jowett S Barton P Malottki K Hyde C Gibbs S Clinical and cost effectiveness of treatments for pulmonary arterial hypertension (PAH) within their licensed indications [updated 21\/02\/2008] West Midlands Health Technology Assessment Collaboration 2008"},{"issue":"10","key":"10.1002\/14651858.CD004434.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions","volume":"65","author":"Denton","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1476-5381.1995.tb15868.x","article-title":"Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors","volume":"115","author":"Filep","year":"1995","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Gali\u00e8","year":"2009","journal-title":"European Respiratory Journal"},{"issue":"1-3","key":"10.1002\/14651858.CD004434.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-2999(96)00125-2","article-title":"Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig trachea","volume":"304","author":"Gater","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1002\/14651858.CD004434.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.101.17.2066","article-title":"Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension","volume":"101","author":"Hasuda","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","article-title":"Results of European post-marketing surveillance of bosentan in pulmonary hypertension","volume":"30","author":"Humbert","year":"2007","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/cvr\/27.12.2125","article-title":"Endothelin receptors in cultured adult rat cardiac fibroblasts","volume":"27","author":"Katwa","year":"1993","journal-title":"Cardiovascular Research"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/019021400404555","article-title":"Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase","volume":"26","author":"Kim","year":"2000","journal-title":"Experimental Lung Research"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.rmed.2006.01.021","article-title":"Treatments for pulmonary arterial hypertension","volume":"100","author":"Liu","year":"2006","journal-title":"Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1006\/bbrc.1995.2560","article-title":"Endothelin induced collagen remodeling in experimental pulmonary hypertension","volume":"215","author":"Mansoor","year":"1995","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub5-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","article-title":"Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing","volume":"161","author":"Miyamoto","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0112|cit112","unstructured":"Types of Pulmonary Hypertension website: http:\/\/www.nhlbi.nih.gov\/health\/health-topics\/topics\/pah\/types.html"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub5-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002994.pub2","article-title":"Prostacyclin for pulmonary hypertension in adults","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0114|cit114","first-page":"342","article-title":"The case for treatment of selected patients with primary pulmonary hypertension","volume":"134","author":"Reeves","year":"1986","journal-title":"The American Review of Respiratory Disease"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub5-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0117|cit117","doi-asserted-by":"crossref","unstructured":"Seibold J Badesch D Gali\u00e8 N Langleben D Naeije R Simonneau G Sitaxsentan, a selective endothelin-a receptor antagonist, improves exercise capacity in pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD) Chest 2005 219S","DOI":"10.1378\/chest.128.4_MeetingAbstracts.219S"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09031936.98.12020265","article-title":"Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension","volume":"12","author":"Sitbon","year":"1998","journal-title":"The European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD004434.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1165\/ajrcmb.25.1.4331","article-title":"Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling","volume":"25","author":"Wort","year":"2001","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub5-BIB0121|cit121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub2","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","author":"Liu","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub5-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub3","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","author":"Liu","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub5-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub4","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","author":"Liu","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004434.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004434.pub5\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T11:32:38Z","timestamp":1714995158000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004434.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":123,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004434.pub5","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD004434.pub6","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,28]]}}}